CN100581585C - 癌症治疗药 - Google Patents
癌症治疗药 Download PDFInfo
- Publication number
- CN100581585C CN100581585C CN01816215A CN01816215A CN100581585C CN 100581585 C CN100581585 C CN 100581585C CN 01816215 A CN01816215 A CN 01816215A CN 01816215 A CN01816215 A CN 01816215A CN 100581585 C CN100581585 C CN 100581585C
- Authority
- CN
- China
- Prior art keywords
- amrubicin
- herceptin
- cancer
- hydrochloride
- drug combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
Description
CI值 | D<sub>1</sub> | D<sub>2</sub> | Df<sub>1</sub> | Df<sub>2</sub> | |
本发明(盐酸氨柔比星醇) | 0.38 | 0.239 | 0.119 | 0.671 | 6.312 |
对照化合物(盐酸阿霉素) | 0.92 | 0.373 | 0.187 | 0.434 | 6.312 |
盐酸氨柔比星醇和Herceptin的用量比 | CI值 | D<sub>1</sub> | D<sub>2</sub> | Df<sub>1</sub> | Df<sub>2</sub> |
2∶1 | 0.38 | 0.239 | 0.119 | 0.671 | 6.312 |
4∶1 | 0.33 | 0.212 | 0.053 | 0.671 | 6.312 |
8∶1 | 0.42 | 0.279 | 0.035 | 0.671 | 6.312 |
CI值 | D<sub>1</sub> | D<sub>2</sub> | Df<sub>1</sub> | Df<sub>2</sub> | |
本发明(盐酸氨柔比星) | 0.17 | 1.267 | 0.032 | 7.542 | 6.312 |
Claims (2)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP228239/2000 | 2000-07-28 | ||
JP228239/00 | 2000-07-28 | ||
JP2000228239 | 2000-07-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102523811A Division CN101732333B (zh) | 2000-07-28 | 2001-07-26 | 癌症治疗药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1466464A CN1466464A (zh) | 2004-01-07 |
CN100581585C true CN100581585C (zh) | 2010-01-20 |
Family
ID=18721568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102523811A Expired - Fee Related CN101732333B (zh) | 2000-07-28 | 2001-07-26 | 癌症治疗药 |
CN01816215A Expired - Fee Related CN100581585C (zh) | 2000-07-28 | 2001-07-26 | 癌症治疗药 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102523811A Expired - Fee Related CN101732333B (zh) | 2000-07-28 | 2001-07-26 | 癌症治疗药 |
Country Status (13)
Country | Link |
---|---|
US (3) | US7449181B2 (zh) |
EP (1) | EP1308168B1 (zh) |
JP (1) | JP5117660B2 (zh) |
KR (1) | KR20030019623A (zh) |
CN (2) | CN101732333B (zh) |
AT (1) | ATE397458T1 (zh) |
AU (1) | AU2001276689A1 (zh) |
CA (1) | CA2417255C (zh) |
DE (1) | DE60134324D1 (zh) |
DK (1) | DK1308168T3 (zh) |
ES (1) | ES2307633T3 (zh) |
TW (1) | TWI317285B (zh) |
WO (1) | WO2002009754A1 (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
DK1282443T3 (da) * | 2000-05-19 | 2010-01-04 | Genentech Inc | Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi |
JP4786871B2 (ja) * | 2002-03-18 | 2011-10-05 | 大日本住友製薬株式会社 | 肺癌治療剤 |
FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
EP1807106A2 (en) * | 2004-10-05 | 2007-07-18 | Oregon Health and Science University | Compositions and methods for treating disease |
CN100464783C (zh) * | 2004-11-22 | 2009-03-04 | 山东蓝金生物工程有限公司 | 一种含抗肿瘤抗生素的抗癌药物组合物 |
CN102580084B (zh) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
CN103251946A (zh) | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
SI2132573T1 (sl) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
ES2583377T3 (es) * | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
WO2010051502A2 (en) | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
SG174378A1 (en) | 2009-03-20 | 2011-10-28 | Genentech Inc | Bispecific anti-her antibodies |
CA2761280A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
EP2536748B1 (en) | 2010-02-18 | 2014-08-20 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
RU2014126098A (ru) | 2011-11-30 | 2016-01-27 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
CN104813168B (zh) | 2012-11-30 | 2017-10-20 | 霍夫曼-拉罗奇有限公司 | 需要pd‑l1抑制剂综合疗法的患者的鉴定 |
US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
CN107349426B (zh) * | 2017-07-12 | 2018-03-23 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH035397B2 (zh) | 1983-09-30 | 1991-01-25 | Sumitomo Pharma |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185432A (en) * | 1986-02-26 | 1993-02-09 | Oncogen | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5077220A (en) * | 1988-08-26 | 1991-12-31 | John Muir Cancer & Aging Institute | Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells |
JPH035397A (ja) | 1989-05-31 | 1991-01-11 | Toshiba Corp | 酸化物結晶薄膜の気相成長方法 |
JP3005397B2 (ja) | 1993-09-06 | 2000-01-31 | 関西日本電気ソフトウェア株式会社 | デッドロック多発自動回避方式 |
US5686278A (en) * | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
CN1164238A (zh) * | 1994-09-12 | 1997-11-05 | 国际生物免疫有限公司 | 抗人结肠癌相关抗原的单克隆抗体及其应用 |
BR9707495A (pt) * | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
CN1082187C (zh) * | 1996-11-26 | 2002-04-03 | 北京市肿瘤防治研究所 | 一种检测雌激素受体水平的生物试剂及免疫组化方法 |
KR100565883B1 (ko) * | 1997-01-22 | 2006-03-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 응고 및 종양 치료용 조직 인자 방법 및 조성물 |
US20030068318A1 (en) * | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
-
2001
- 2001-07-24 TW TW90118039A patent/TWI317285B/zh not_active IP Right Cessation
- 2001-07-26 JP JP2002501211A patent/JP5117660B2/ja not_active Expired - Lifetime
- 2001-07-26 AT AT01954360T patent/ATE397458T1/de active
- 2001-07-26 ES ES01954360T patent/ES2307633T3/es not_active Expired - Lifetime
- 2001-07-26 CN CN2009102523811A patent/CN101732333B/zh not_active Expired - Fee Related
- 2001-07-26 WO PCT/JP2001/006467 patent/WO2002009754A1/ja active IP Right Grant
- 2001-07-26 AU AU2001276689A patent/AU2001276689A1/en not_active Abandoned
- 2001-07-26 US US10/333,978 patent/US7449181B2/en not_active Expired - Fee Related
- 2001-07-26 CA CA 2417255 patent/CA2417255C/en not_active Expired - Fee Related
- 2001-07-26 KR KR10-2003-7001194A patent/KR20030019623A/ko not_active Application Discontinuation
- 2001-07-26 DK DK01954360T patent/DK1308168T3/da active
- 2001-07-26 CN CN01816215A patent/CN100581585C/zh not_active Expired - Fee Related
- 2001-07-26 DE DE60134324T patent/DE60134324D1/de not_active Expired - Lifetime
- 2001-07-26 EP EP20010954360 patent/EP1308168B1/en not_active Expired - Lifetime
-
2007
- 2007-06-11 US US11/761,264 patent/US7879327B2/en not_active Expired - Fee Related
-
2010
- 2010-12-23 US US12/978,275 patent/US9139658B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH035397B2 (zh) | 1983-09-30 | 1991-01-25 | Sumitomo Pharma |
Also Published As
Publication number | Publication date |
---|---|
JP5117660B2 (ja) | 2013-01-16 |
EP1308168B1 (en) | 2008-06-04 |
ATE397458T1 (de) | 2008-06-15 |
EP1308168A1 (en) | 2003-05-07 |
EP1308168A4 (en) | 2004-09-01 |
AU2001276689A1 (en) | 2002-02-13 |
US20030157097A1 (en) | 2003-08-21 |
ES2307633T3 (es) | 2008-12-01 |
US7449181B2 (en) | 2008-11-11 |
CN101732333A (zh) | 2010-06-16 |
DK1308168T3 (da) | 2008-07-28 |
US9139658B2 (en) | 2015-09-22 |
KR20030019623A (ko) | 2003-03-06 |
DE60134324D1 (de) | 2008-07-17 |
US7879327B2 (en) | 2011-02-01 |
WO2002009754A1 (fr) | 2002-02-07 |
CN1466464A (zh) | 2004-01-07 |
CN101732333B (zh) | 2012-08-15 |
CA2417255A1 (en) | 2003-01-24 |
CA2417255C (en) | 2011-08-02 |
US20110104160A1 (en) | 2011-05-05 |
US20080031881A1 (en) | 2008-02-07 |
TWI317285B (en) | 2009-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100581585C (zh) | 癌症治疗药 | |
US10092567B2 (en) | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | |
EP3581182B1 (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
TWI231211B (en) | Compositions and methods for enhancing the bioavailability of pharmaceutical agents | |
EP1265635A1 (en) | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody | |
US20080125447A1 (en) | Combination Therapy | |
US20030138430A1 (en) | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody | |
CN111918656B (zh) | 用于联合治疗的抗癌药物组合物 | |
JP7381115B2 (ja) | 組成物及びがん治療用医薬品の調製におけるその応用 | |
US20220313652A1 (en) | Use of compound or pharmaceutically acceptable salt, dimer or trimer thereof in manufacture of medicament for treating cancer | |
CN111821304A (zh) | 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途 | |
CN117281902A (zh) | 一种药物组合物在制备治疗黑色素瘤产品中的应用 | |
CN117547605A (zh) | 一种lag-3单抗在制备治疗黑色素瘤产品中应用 | |
WO2017133599A1 (zh) | 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物 | |
US20220378776A1 (en) | Drug combination of quinoline derivative and pd-1 monoclonal antibody | |
CN116407640A (zh) | 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 | |
CN110960679A (zh) | 一种抗肿瘤的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NIPPO SUMITOMO PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: SUMITOMO PHARMACEUTICALS CO., LTD. Effective date: 20060317 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060317 Address after: Osaka City, Osaka of Japan Applicant after: Dainippon Sumitomo Pharma Co., Ltd. Address before: Osaka Japan Applicant before: Sumitomo Chemical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100120 Termination date: 20170726 |